CD274 and hepatocellular carcinoma: Following nivolumab, pembrolizumab, another anti-PD-1 agent, was approved for the treatment of HCC, while numerous agents targeting different immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), PD-1, and PD-L1 are currently under evaluation as monotherapy or as combination treatment in various studies [6].